Focused On-demand Library for Zinc finger protein ZIC 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q15915

UPID:

ZIC1_HUMAN

Alternative names:

Zinc finger protein 201; Zinc finger protein of the cerebellum 1

Alternative UPACC:

Q15915; Q2M3N1

Background:

Zinc finger protein ZIC 1, also known as Zinc finger protein 201 and Zinc finger protein of the cerebellum 1, plays a pivotal role in neurogenesis and organogenesis of the CNS. It is crucial for the early development of the dorsal spinal cord and cerebellum maturation, influencing the spatial distribution of mossy fiber neurons within the pontine gray nucleus and regulating their axon pathway choices.

Therapeutic significance:

Linked to diseases such as Craniosynostosis 6 and Structural brain anomalies with impaired intellectual development and craniosynostosis, Zinc finger protein ZIC 1's understanding could pave the way for innovative therapeutic strategies targeting these genetic disorders.